- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06196632
Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based Therapy
February 5, 2024 updated by: Qilu Hospital of Shandong University
Development and Validation of Logistic Regression Models to Predict Durable Functional Cure in Patients With Chronic Hepatitis B After Pegylated Interferon Alpha-2b Based Therapy
Hepatitis B virus (HBV) infection is prevalent across the world.
Functional cure is the optimal endpoint of antiviral therapy for chronic hepatitis B virus (HBV) infection.
Currently available anti-HBV therapy includes nucleoside analogs (NAs) and peginterferon-α (Peg-IFNα).
Combination of Peg-IFNα and NAs, each with different mechanisms of action, is an attractive approach for treating chronic HBV infection.
In this study, we aim to establish logistic regression models to predict durable functional cure in patients with CHB treated by combination of Peg-IFNα and NAs, which might be useful for clinical physicians to make personalized treatment decisions.
These models will be constructed using baseline routine clinical laboratory indicators with high diagnostic accuracy.
These models might be widely applicable to almost all medical institutions and will effectively promote the application of Peg IFN α plus NAs therapy in clinical work.
The findings in this study might greatly improve the functional cure rate of CHB and reducing the incidence rate and mortality of HBV related end-stage liver diseases.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shuai Gao, MD;PhD
- Phone Number: +86-18560088213
- Email: qilugaoshuai@sdu.edu.cn
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Recruiting
- Qilu Hospital of Shandong University
-
Contact:
- Shuai Gao, MD;PhD
- Phone Number: +86-18560088213
- Email: qilugaoshuai@sdu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
The participants were retrospectively enrolled from more than 10 hospitals in China.
Description
Inclusion Criteria:
- 1. Sign an informed consent form;
- 2. HBsAg (+), and the course of the disease exceeds six months;
- 3. Age range from 16 to 70 years old;
- 4. Female participants of childbearing age who had a negative pregnancy test before the trial and were able to take effective contraceptive measures;
- 5. During the treatment period, within six months after the end of treatment, the patients agrees to use contraception
Exclusion Criteria:
- 1. Patients with a known history of allergy to Peg-IFNα and NAs;
- 2. Co-infection with other virus such as HAV, HCV, HDV, HEV, HIV, etc;
- 3. Patients with liver cirrhosis or a Child Pugh score of 7 or above;
- 4. History or evidence of liver disease caused by other factors (such as autoimmune liver disease, alcoholic liver disease, non-alcoholic fatty liver disease, drug-induced hepatitis, hepatolenticular degeneration, etc.);
- 5. Pregnant or lactating women; Have a history of alcohol or drug abuse within the year prior to the trial enrollment screening;
- 6. Neutrophil count<1.5 × 109/L or hemoglobin<100g/L or platelet count<80 × 109/L; During the trial enrollment screening, serum creatinine was higher than the upper normal limit;
- 7. A history of severe diseases in important organs and tissues such as the heart, brain, kidneys, retina, and muscles;
- 8. Having a history of mental illness or a family history of mental illness, or a Hamilton Depression Scale score greater than 7 points;
- 9. History of endocrine system or autoimmune diseases, such as thyroid disease, diabetes, systemic lupus erythematosus, sarcoidosis, autoimmune thrombocytopenic purpura, etc;
- 10. History of malignant tumors;
- 11. During the trial enrollment screening, suspicious liver malignant tumors were detected by ultrasound, or AFP was greater than 100ng/mL or AFP cannot remain stable within 3 months prior to the experiment;
- 12. Has a history of important organ transplantation;
- 13. Other diseases that researchers believe are not suitable for inclusion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
"de novo" strategy-HBeAg positive
HBeAg positive patients treated with simultaneous administration of NA and Peg-IFN
|
Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs
|
"de novo" strategy-HBeAg negative
HBeAg positive patients treated with simultaneous administration of NA and Peg-IFN
|
Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs
|
"add-on" strategy-HBeAg positive
HBeAg positive patients treated with NA followed by addition of Peg-IFN.
|
Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs
|
"add-on" strategy-HBeAg negative
HBeAg negative patients treated with NA followed by addition of Peg-IFN.
|
Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional cure of chronic hepatit B
Time Frame: 48 weeks
|
The level of hepatitis B surface antigen (HBsAg) is below 0.05IU/ml.
|
48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 6, 2024
Primary Completion (Estimated)
July 31, 2024
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
December 25, 2023
First Submitted That Met QC Criteria
December 25, 2023
First Posted (Actual)
January 9, 2024
Study Record Updates
Last Update Posted (Actual)
February 7, 2024
Last Update Submitted That Met QC Criteria
February 5, 2024
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Disease Attributes
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Hepatitis, Chronic
- Chronic Disease
- Hepatitis B
- Hepatitis
- Hepatitis B, Chronic
Other Study ID Numbers
- KYLL-2023(ZM)-726
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B, Chronic
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
Clinical Trials on Peginterferon-α; Nucleoside analogs
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Sun Yat-sen UniversityUnknownHepatitis B, ChronicChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityPeking University; First People's Hospital of Foshan; Shenzhen Third People's...UnknownChronic Hepatitis BChina
-
Ministry of Health, MalaysiaUnknown
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWuhan Union Hospital, ChinaUnknownThe Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAgChronic Hepatitis BChina
-
Beijing Ditan HospitalUnknownChronic Hepatitis B InfectionChina
-
Beijing Ditan HospitalUnknownChronic Hepatitis B InfectionChina
-
Yao XieUnknownChronic Hepatitis B InfectionChina
-
Beijing Ditan HospitalUnknownChronic Hepatitis B InfectionChina
-
Beijing Ditan HospitalUnknown